Cogent Biosciences (COGT) Stock Forecast, Price Target & Predictions
COGT Stock Forecast
Cogent Biosciences stock forecast is as follows: an average price target of $18.83 (represents a 109.69% upside from COGT’s last price of $8.98) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.
COGT Price Target
The average price target for Cogent Biosciences (COGT) is $18.83 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $24.00 to $15.00. This represents a potential 109.69% upside from COGT's last price of $8.98.
COGT Analyst Ratings
According to 6 Wall Street analysts, Cogent Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for COGT stock is 0 'Strong Buy' (0.00%), 6 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cogent Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 24, 2024 | David Lebowitz | Citigroup | $15.00 | $10.65 | 40.85% | 67.04% |
| Sep 03, 2024 | David Lebowitz | Citigroup | $13.00 | $10.95 | 18.72% | 44.77% |
| Sep 03, 2024 | Robert Burns | H.C. Wainwright | $17.00 | $11.37 | 49.52% | 89.31% |
| Mar 30, 2024 | Kelly Shi | Jefferies | $20.00 | $6.72 | 197.62% | 122.72% |
| Dec 14, 2022 | - | Needham | $24.00 | $12.32 | 94.81% | 167.26% |
| Jun 17, 2022 | Chris Raymond | Raymond James | $22.00 | $9.19 | 139.39% | 144.99% |
| Jun 10, 2022 | Christopher Liu | Leerink Partners | $15.00 | $10.74 | 39.66% | 67.04% |
The latest Cogent Biosciences stock forecast, released on Sep 24, 2024 by David Lebowitz from Citigroup, set a price target of $15.00, which represents a 40.85% increase from the stock price at the time of the forecast ($10.65), and a 67.04% increase from COGT last price ($8.98).
Cogent Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 4 |
| Avg Price Target | - | $15.00 | $16.25 |
| Last Closing Price | $8.98 | $8.98 | $8.98 |
| Upside/Downside | -100.00% | 67.04% | 80.96% |
In the current month, the average price target of Cogent Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cogent Biosciences's last price of $8.98. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 24, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | Citigroup | Buy | Buy | Hold |
| Sep 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 14, 2022 | Needham | - | Buy | Initialise |
| Dec 13, 2022 | Guggenheim | Buy | Buy | Hold |
| Jun 17, 2022 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 10, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Cogent Biosciences's last stock rating was published by Citigroup on Sep 24, 2024. The company gave COGT a "Buy" rating, the same as its previous rate.
Cogent Biosciences Financial Forecast
Cogent Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $7.03M | $15.29M | $1.02M | $3.14M | $3.05M | $2.22M |
| Avg Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | $50.00K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $2.06M |
| High Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | $50.00K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $2.47M |
| Low Forecast | $1.68M | $1.09M | $588.63K | $179.93K | - | - | - | $50.00K | $2.00M | $3.74M | $3.52M | $3.25M | $3.11M | $1.65M |
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 13 | 9 | 8 | 6 | 10 | 6 | 14 |
| Surprise % | - | - | - | - | - | - | - | 0.00% | 3.52% | 4.08% | 0.29% | 0.97% | 0.98% | 1.08% |
Cogent Biosciences's average Quarter revenue forecast for Jun 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. COGT's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of - (Dec 20).
Cogent Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 13 | 9 | 8 | 6 | 10 | 6 | 14 |
| EBITDA | - | - | - | - | - | - | - | $-11.32M | $-5.80M | $2.61M | $-11.61M | $-10.19M | $-11.36M | $-6.42M |
| Avg Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | $10.00K | $-7.83M | $748.80K | $704.93K | $649.45K | $-9.40M | $-5.92M |
| High Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | $10.00K | $-6.26M | $748.80K | $704.93K | $649.45K | $-7.52M | $-4.74M |
| Low Forecast | $335.82K | $217.17K | $117.73K | $35.99K | - | - | - | $10.00K | $-9.39M | $748.80K | $704.93K | $649.45K | $-11.28M | $-7.11M |
| Surprise % | - | - | - | - | - | - | - | -1132.21% | 0.74% | 3.49% | -16.46% | -15.68% | 1.21% | 1.08% |
9 analysts predict COGT's average Quarter EBITDA for Mar 20 to be $-7.83M, with a high of $-6.26M and a low of $-9.39M. This is -399.74% lower than Cogent Biosciences's previous annual EBITDA (Dec 19) of $2.61M.
Cogent Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 13 | 9 | 8 | 6 | 10 | 6 | 14 |
| Net Income | - | - | - | - | - | - | - | $-11.34M | $-6.09M | $2.30M | $-11.92M | $-10.52M | $-11.69M | $-6.74M |
| Avg Forecast | $-58.83M | $-59.71M | $-62.35M | $-63.46M | $-63.88M | $-62.38M | $-55.28M | $-50.61M | $-8.22M | $-107.18M | $-123.06M | $-153.23M | $-9.67M | $-6.21M |
| High Forecast | $-58.83M | $-59.71M | $-62.35M | $-53.26M | $-55.22M | $-62.38M | $-55.28M | $-50.61M | $-6.58M | $-107.18M | $-123.06M | $-153.23M | $-7.74M | $-4.97M |
| Low Forecast | $-58.83M | $-59.71M | $-62.35M | $-69.12M | $-72.54M | $-62.38M | $-55.28M | $-50.61M | $-9.87M | $-107.18M | $-123.06M | $-153.23M | $-11.60M | $-7.46M |
| Surprise % | - | - | - | - | - | - | - | 0.22% | 0.74% | -0.02% | 0.10% | 0.07% | 1.21% | 1.08% |
Cogent Biosciences's average Quarter net income forecast for Mar 20 is $-8.22M, with a range of $-9.87M to $-6.58M. COGT's average Quarter net income forecast represents a -458.05% decrease compared to the company's last Quarter net income of $2.30M (Dec 19).
Cogent Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 13 | 9 | 8 | 6 | 10 | 6 | 14 |
| SG&A | - | - | - | - | - | - | - | $5.35M | $3.67M | $2.69M | $2.72M | $3.06M | $2.49M | $1.06M |
| Avg Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | $57.01K | $2.28M | $4.27M | $4.02M | $3.70M | $2.06M | $981.60K |
| High Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | $57.01K | $2.28M | $4.27M | $4.02M | $3.70M | $2.47M | $1.18M |
| Low Forecast | $1.91M | $1.24M | $671.15K | $205.16K | - | - | - | $57.01K | $2.28M | $4.27M | $4.02M | $3.70M | $1.65M | $785.28K |
| Surprise % | - | - | - | - | - | - | - | 93.81% | 1.61% | 0.63% | 0.68% | 0.83% | 1.21% | 1.08% |
Cogent Biosciences's average Quarter SG&A projection for Jun 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to COGT last annual SG&A of $5.35M (Dec 20).
Cogent Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | - | - | - | 13 | 9 | 8 | 6 | 10 | 6 | 14 |
| EPS | - | - | - | - | - | - | - | $-0.59 | $-0.80 | $0.28 | $-1.56 | $-1.36 | $-1.56 | $-2.64 |
| Avg Forecast | $-0.53 | $-0.54 | $-0.57 | $-0.58 | $-0.58 | $-0.57 | $-0.56 | $-0.51 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.33 |
| High Forecast | $-0.53 | $-0.54 | $-0.57 | $-0.48 | $-0.50 | $-0.57 | $-0.56 | $-0.51 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.27 |
| Low Forecast | $-0.53 | $-0.54 | $-0.57 | $-0.63 | $-0.66 | $-0.57 | $-0.56 | $-0.51 | $-1.20 | $-1.08 | $-1.24 | $-1.54 | $-1.28 | $-0.40 |
| Surprise % | - | - | - | - | - | - | - | 1.16% | 0.67% | -0.26% | 1.26% | 0.88% | 1.22% | 8.00% |
According to 9 Wall Street analysts, Cogent Biosciences's projected average Quarter EPS for Mar 20 is $-1.20, with a low estimate of $-1.20 and a high estimate of $-1.20. This represents a -528.57% decrease compared to COGT previous annual EPS of $0.28 (Dec 19).
Cogent Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $1.73 | $33.86 | 1857.23% | Buy |
| ZNTL | Zentalis Pharmaceuticals | $3.18 | $21.86 | 587.42% | Buy |
| LIFE | aTyr Pharma | $1.90 | $11.00 | 478.95% | Buy |
| OLMA | Olema Pharmaceuticals | $7.87 | $28.50 | 262.13% | Buy |
| SANA | Sana Bio | $2.35 | $8.00 | 240.43% | Buy |
| LRMR | Larimar Therapeutics | $6.13 | $20.33 | 231.65% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| KURA | Kura Oncology | $10.06 | $26.00 | 158.45% | Buy |
| CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
| ANAB | AnaptysBio | $21.17 | $52.00 | 145.63% | Buy |
| KALV | KalVista Pharmaceuticals | $9.33 | $22.67 | 142.98% | Buy |
| SNDX | Syndax Pharmaceuticals | $15.60 | $34.30 | 119.87% | Buy |
| COGT | Cogent Biosciences | $8.98 | $18.83 | 109.69% | Buy |
| KROS | Keros Therapeutics | $53.84 | $102.60 | 90.56% | Buy |
| IDYA | IDEAYA Biosciences | $26.60 | $46.58 | 75.11% | Buy |
| KNSA | Kiniksa Pharmaceuticals | $21.09 | $36.33 | 72.26% | Buy |
| MGTX | MeiraGTx | $5.92 | $9.00 | 52.03% | Buy |
| MRSN | Mersana Therapeutics | $1.98 | $3.00 | 51.52% | Buy |
| PTGX | Protagonist Therapeutics | $41.65 | $50.00 | 20.05% | Buy |
| VRNA | Verona Pharma | $37.86 | $33.86 | -10.57% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |